This first positive trial regarding immunotherapy in MPM is in contrast with non-small cell lung cancer (NSCLC), where mono- immunotherapy targeting PD-(L)1 has become the standard of care based on many positive trials from 2015, showing long-term overall survival [6,7,8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.